Shire plc

Shire plc files its first submission to the US FDA for its new plasma manufacturing facility in Covington, GA

DUBLIN, 02-Jan-2018 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that…

6 years ago

Thomas Dittrich appointed Chief Financial Officer and Executive member of the Board of Directors at Shire plc

DUBLIN, 21-Nov-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, today announced that…

6 years ago

Shire plc: total number of voting rights in the Company is 908,114,281 as of July 31, 2017

DUBLIN, 02-Aug-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct…

7 years ago

Shire plc: U.S. FDA acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for SHP465

Lexington, Mass., USA, 20-Jan-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration…

7 years ago

Shire plc: U.S. FDA approved the BAXJECT III reconstitution system for ADYNOVATE

New system reduces number of steps in the treatment process for hemophilia A patients on ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]…

8 years ago